Matteo Simonelli
Overview
Explore the profile of Matteo Simonelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bono B, Grimi A, Di Toro A, Ninatti G, Franzini A, Rossini Z, et al.
Neurosurgery
. 2025 Jan;
PMID: 39878484
Background And Objectives: Understanding and managing seizure activity is crucial in neuro-oncology, especially for highly epileptogenic lesions like isocitrate dehydrogenase (IDH)-mutant gliomas. Advanced MRI techniques such as diffusion tensor imaging...
2.
Cella E, Bosio A, Persico P, Caccese M, Padovan M, Losurdo A, et al.
Cancer Treat Rev
. 2024 Dec;
132:102866.
PMID: 39709267
No abstract available.
3.
Cella E, Bosio A, Persico P, Caccese M, Padovan M, Losurdo A, et al.
Cancer Treat Rev
. 2024 Nov;
131:102850.
PMID: 39531943
Gliomas are the most common primary malignant brain tumours in adults. Despite decades of research into novel therapeutic approaches, the prognosis remains poor. PARP1-2 are critical for DNA repair, cell...
4.
Scirgolea C, Sottile R, De Luca M, Susana A, Carnevale S, Puccio S, et al.
Nat Immunol
. 2024 Aug;
25(10):1845-1857.
PMID: 39198631
CD8 T cells control tumors but inevitably become dysfunctional in the tumor microenvironment. Here, we show that sodium chloride (NaCl) counteracts T cell dysfunction to promote cancer regression. NaCl supplementation...
5.
Tropeano M, Raspagliesi L, Bono B, Baram A, Rossini Z, Franzini A, et al.
Acta Neurochir (Wien)
. 2024 Apr;
166(1):196.
PMID: 38676720
Background: The prognostic value of the extent of resection in the management of Glioblastoma is a long-debated topic, recently widened by the 2022 RANO-Resect Classification, which advocates for the resection...
6.
Di Nunno V, Lombardi G, Simonelli M, Minniti G, Mastronuzzi A, Di Ruscio V, et al.
J Neurooncol
. 2024 Mar;
167(1):145-154.
PMID: 38457090
Purpose: Adult Diffuse midline glioma (DMG) is a very rare disease. DMGs are currently treated with radiotherapy and chemotherapy even if only a few retrospective studies assessed the impact on...
7.
Miele E, Anghileri E, Calatozzolo C, Lazzarini E, Patrizi S, Ciolfi A, et al.
Cancer Lett
. 2024 Feb;
588:216711.
PMID: 38423245
Five-year glioblastoma (GBM) survivors (LTS) are the minority of the isocitrate dehydrogenase (IDH)-wild-type GBM patients, and their molecular fingerprint is still largely unexplored. This multicenter retrospective study analyzed a large...
8.
Robbrecht D, Grob J, Bechter O, Simonelli M, Doger B, Borbath I, et al.
Clin Transl Sci
. 2024 Feb;
17(2):e13736.
PMID: 38362837
SAR439459, a 'second-generation' human anti-transforming growth factor-beta (TGFβ) monoclonal antibody, inhibits all TGFβ isoforms and improves the antitumor activity of anti-programmed cell death protein-1 therapeutics. This study reports the pharmacodynamics...
9.
Losurdo A, Di Muzio A, Cianciotti B, Dipasquale A, Persico P, Barigazzi C, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339353
Glioblastoma (GBM) is the most aggressive and lethal primary brain tumor, bearing a survival estimate below 10% at five years, despite standard chemoradiation treatment. At recurrence, systemic treatment options are...
10.
Dipasquale A, Franceschi E, Lombardi G, Simonelli M
Neurooncol Adv
. 2024 Feb;
6(1):vdae003.
PMID: 38312228
No abstract available.